ResourceDrug Discovery & Development
The landscape of nucleic acid therapeutics
26 May 2026The rapid expansion of nucleic acid therapeutics, from early antisense oligos to today’s mRNA vaccines and CRISPR‑based gene therapies, has created new analytical challenges. As modalities diversify and grow in complexity, labs must characterize structures, modifications, and stability with far greater precision.
Explore this resource to understand key therapeutic classes, from approved drugs like nusinersen to emerging formats such as self-amplifying RNA (saRNA). Gain clarity on structural components, critical nucleotide modifications, and the technologies shaping the next generation of oligo and mRNA medicines.
Related products
Request Quote for All Products
PrimeMax™ CPG
LGC Diagnostics & Genomics - Biosearch Technologies Oligo-SynthesisA CPG solid support designed to maximise productivity and synthesis efficiency for oligonucleotide manufacturing.
Links
Tags
Protein ExpressionProtein expression is the utilization of cell machinery for the synthesis of proteins and has become a critical tool in biotherapeutic, genomic, and proteomic research. Produce recombinant proteins with expression vectors in combination with a host cell suitable for high-level protein expression. For production of toxic proteins, consider cell-free expression vectors. Create and monitor post-translational modifications with protein modification kits. Find the best protein expression products in our peer-reviewed product directory: compare products, check customer reviews and receive pricing direct from manufacturers.OligosVaccinesmRNA